Goldman Urology Clinic has recorded a cumulative 6,000 cases of benign prostatic hyperplasia (BPH) surgery, demonstrating the competitiveness of its patient-customized treatment system. This achievement is attributed to a treatment strategy that comprehensively considers prostate size, symptoms, and recovery plans, leading to consistent positive outcomes.
Benign prostatic hyperplasia (BPH) is known as a common disease among middle-aged and elderly men. It is characterized by the prostate gland becoming excessively enlarged and compressing the urethra, thereby causing lower urinary tract symptoms (LUTS) such as frequent urination, nocturia, a feeling of incomplete bladder emptying (residual urine sensation), and delayed urination. In the early stages of BPH, symptoms can be controlled with medication. However, if the response to medication decreases or symptoms recur and worsen, surgical treatment becomes necessary. At this point, it is crucial to comprehensively consider not only the size and shape of the prostate but also symptoms, presence of complications, chronic diseases, anesthesia conditions, and recovery plans, to guide the patient in selecting the most appropriate surgical technique.
In accordance with these treatment principles, Goldman Urology Clinic has strived to introduce the latest surgical techniques and refine clinical protocols. The clinic has expanded its spectrum of selectable treatments based on the patient's condition, including the Rezum procedure, which injects high-temperature steam to necrotize and shrink hypertrophied tissue; Aquablation (Waterjet Robotic Surgery), which precisely resects prostate tissue without thermal damage using a high-pressure AI robot waterjet; and HoLEP (Holmium Laser Enucleation of the Prostate) surgery, which completely removes hypertrophied tissue with a holmium laser.
Furthermore, by operating various methods together, such as iTind, which widens the prostatic urethra, and UroLift, which minimizes the burden of surgical resection, the clinic has established customized treatment strategies based on the patient's prostate size, shape, and symptom severity.
In addition, Goldman Urology Clinic continues its ongoing research on BPH based on over 2 million clinical data points accumulated over more than 20 years. These research achievements are accumulated as clinical outcomes in actual medical practice, leading to positive evaluations. Indeed, based on its clinical experience with waterjet robotic surgery, the clinic has presented related research findings at academic conferences and has verified and complemented the safety and efficacy of the latest surgical techniques in real clinical settings.
Lee Chang-ki, the chief director of Goldman Urology Clinic, stated, "The outcomes of BPH surgery inevitably vary depending on the medical team's proficiency, the accuracy of pre-operative evaluation, and the post-operative management system. The medical staff across all Goldman Urology Clinic branches has enhanced treatment consistency and stability through a system of regular clinical data sharing and collaborative development of treatment protocols." He added, "Especially for BPH, since each patient experiences discomfort differently, and concomitant diseases or recovery plans also vary, our core principle is an approach that offers the necessary surgical technique at the time it is needed for the patient, rather than adhering to a single method as the definitive answer."